Literature DB >> 26318911

Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma.

Yan Li1, Xiuhe Pan1, Xiao Peng1, Shubo Li2, Yanchun Zhou3, Xiaoxuan Zheng3, Mingcai Li4,5.   

Abstract

OBJECTIVE AND
DESIGN: Asthma is thought to result from the generation of T helper type 2 (Th2) responses, leading to bronchial inflammation. Interleukin (IL)-35 is a recently described member of IL-12 cytokine family that plays a critical role in influencing Th cell differentiation and inflammatory processes. The aim of this study was to examine the effect of adenovirus expressing IL-35 (AdIL-35) on allergic airway hyperresponsiveness (AHR) and inflammation in a mouse model of asthma.
METHODS: BALB/c mice were subjected to an established model of allergic airway disease. AdIL-35 was administered intranasally and the effect of IL-35 on Th2 responses, pulmonary inflammation, goblet cell metaplasia, and AHR were assessed.
RESULTS: Transfer of AdIL-35 significantly reduced the severity of AHR and numbers of inflammatory cells and levels of IL-4, IL-5, IL-13, and IL-17 in bronchoalveolar lavage fluid, compared with administration of a control virus. Moreover, AdIL-35 elevated the numbers of CD4+CD25+Foxp3+ regulatory T cells in the lungs. Histological analysis showed that AdIL-35 inhibited allergic lung tissue inflammation and mucus hypersecretion.
CONCLUSION: These results demonstrate that adenovirus-mediated delivery of interleukin-35 gene can mitigate allergic airway inflammation in experimental asthma and suggest that IL-35 may offer a novel therapeutic approach to treat allergic asthma.

Entities:  

Keywords:  Airway inflammation; Allergic asthma; Eosinophils; Hyperresponsiveness; IL-35; Regulatory T cells; Th17 cells

Mesh:

Substances:

Year:  2015        PMID: 26318911     DOI: 10.1007/s00011-015-0858-1

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  46 in total

Review 1.  Immunologic basis of antigen-induced airway hyperresponsiveness.

Authors:  M Wills-Karp
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

2.  A potential immunopathogenic role for reduced IL-35 expression in allergic asthma.

Authors:  Wei Wang; Ping Li; Yi-fei Chen; Jiong Yang
Journal:  J Asthma       Date:  2015-06-05       Impact factor: 2.515

3.  Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells.

Authors:  J Dong; C K Wong; Z Cai; D Jiao; M Chu; C W K Lam
Journal:  Allergy       Date:  2015-05-15       Impact factor: 13.146

4.  IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease.

Authors:  Gregory S Whitehead; Rhonda H Wilson; Keiko Nakano; Lauranell H Burch; Hideki Nakano; Donald N Cook
Journal:  J Allergy Clin Immunol       Date:  2011-09-08       Impact factor: 10.793

5.  IL-35-mediated induction of a potent regulatory T cell population.

Authors:  Lauren W Collison; Vandana Chaturvedi; Abigail L Henderson; Paul R Giacomin; Cliff Guy; Jaishree Bankoti; David Finkelstein; Karen Forbes; Creg J Workman; Scott A Brown; Jerold E Rehg; Michael L Jones; Hsiao-Tzu Ni; David Artis; Mary Jo Turk; Dario A A Vignali
Journal:  Nat Immunol       Date:  2010-10-17       Impact factor: 25.606

Review 6.  Gene therapy for asthma.

Authors:  Phillip Factor
Journal:  Mol Ther       Date:  2003-02       Impact factor: 11.454

Review 7.  Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products.

Authors:  W W Busse; R L Coffman; E W Gelfand; A B Kay; L J Rosenwasser
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

8.  Dendritic cells modulated by cytokine-expressing adenoviruses alleviate eosinophilia and airway hyperresponsiveness in an animal model of asthma.

Authors:  Yi-Ling Ye; Yueh-Lun Lee; Zen-Jai Chuang; Huai-Jean Lai; Chun-Chi Chen; Mi-Hua Tao; Bor-Luen Chiang
Journal:  J Allergy Clin Immunol       Date:  2004-07       Impact factor: 10.793

9.  Interleukin-17 is a negative regulator of established allergic asthma.

Authors:  Silvia Schnyder-Candrian; Dieudonnée Togbe; Isabelle Couillin; Isabelle Mercier; Frank Brombacher; Valérie Quesniaux; Francois Fossiez; Bernhard Ryffel; Bruno Schnyder
Journal:  J Exp Med       Date:  2006-11-13       Impact factor: 14.307

10.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.

Authors:  Ping Shen; Toralf Roch; Vicky Lampropoulou; Richard A O'Connor; Ulrik Stervbo; Ellen Hilgenberg; Stefanie Ries; Van Duc Dang; Yarúa Jaimes; Capucine Daridon; Rui Li; Luc Jouneau; Pierre Boudinot; Siska Wilantri; Imme Sakwa; Yusei Miyazaki; Melanie D Leech; Rhoanne C McPherson; Stefan Wirtz; Markus Neurath; Kai Hoehlig; Edgar Meinl; Andreas Grützkau; Joachim R Grün; Katharina Horn; Anja A Kühl; Thomas Dörner; Amit Bar-Or; Stefan H E Kaufmann; Stephen M Anderton; Simon Fillatreau
Journal:  Nature       Date:  2014-02-23       Impact factor: 49.962

View more
  15 in total

Review 1.  Role of Anti-inflammatory Cytokines IL-35 and IL-37 in Asthma.

Authors:  Daiju Hu
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

2.  IL35 attenuated LPS-induced acute lung injury by regulating macrophage polarization.

Authors:  Shengsong Chen; Jingen Xia; Yi Zhang; Qingyuan Zhan
Journal:  Mol Biol Rep       Date:  2022-06-24       Impact factor: 2.742

Review 3.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Authors:  Shi-Yang Guan; Rui-Xue Leng; Muhammad Imran Khan; Humera Qureshi; Xiang-Pei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

4.  Anti-inflammatory roles of interleukin-35 in the pathogenesis of Japanese cedar pollinosis.

Authors:  Hideaki Kouzaki; Yukihiro Arai; Keigo Nakamura; Takuya Murao; Ichiro Tojima; Shino Shimizu; Atsushi Yuta; Takeshi Shimizu
Journal:  Asia Pac Allergy       Date:  2021-07-21

Review 5.  Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent.

Authors:  Peng Gao; Zhenzhong Su; Xuejiao Lv; Jie Zhang
Journal:  Mediators Inflamm       Date:  2017-04-30       Impact factor: 4.711

Review 6.  Immunoregulatory Functions of the IL-12 Family of Cytokines in Antiviral Systems.

Authors:  Yifei Guo; Wei Cao; Ying Zhu
Journal:  Viruses       Date:  2019-08-22       Impact factor: 5.048

7.  Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis.

Authors:  Motohiko Suzuki; Makoto Yokota; Yoshihisa Nakamura; Shinya Ozaki; Shingo Murakami
Journal:  Allergol Int       Date:  2016-10-02       Impact factor: 5.836

8.  Aberrant Th2 Immune Responses Are Associated With a Reduced Frequency of IL-35-Induced Regulatory T Cells After Allergen Exposure in Patients With Allergic Asthma.

Authors:  Wei Wang; Chaojie Wei; Zhenshun Cheng; Jiong Yang
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764

9.  Different expression levels of interleukin-35 in asthma phenotypes.

Authors:  Wei Li; Ruihan Gao; Tong Xin; Peng Gao
Journal:  Respir Res       Date:  2020-04-16

10.  Interleukin-35 sensitizes monocytes from patients with asthma to glucocorticoid therapy by regulating p38 MAPK.

Authors:  Lei Qian; Donghui Xu; Fangsu Xue; Ming Li; Xushan Wang; Guangliang Liu
Journal:  Exp Ther Med       Date:  2020-03-09       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.